With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.